// App-Quantinova.ai

359 : AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results

Researchers

Presenter

  • Hossein Borghaei

Principal Investigators

  • Melissa Johnson

  • Ramaswamy Govindan

  • Luis Paz-Ares Rodrigues

  • Fiona Blackhall

  • Rene Boosman

  • Stphane Champiat

  • Horst-Dieter Hummel

  • W Victoria Lai

  • Hibiki Udagawa

  • Anne Chiang

  • Afshin Dowlati

  • Christine Hann

  • Ravi Salgia

  • Everett Vokes

  • Mukul Minocha

  • Nooshin Hashemi-Sadraei

  • Aditya Shetty

  • Marie-Anne Damiette Smit

  • Hui Yang

  • Taofeek Owonikoko

Medical Centers

  • Fox Chase Cancer Center, Philadelphia, PA

  • Chris O'Brien Lifehouse, Camperdown, Australia

  • Sarah Cannon Research Institute, Nashville, TN

  • Washington University Medical School, Saint Louis, MO

  • Universidad Complutense and Ciberonc, Madrid, Spain

  • University of Manchester, Manchester, United Kingdom

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Paris-Saclay University, Villejuif, France

  • University of Wurzburg, Wurzburg, Germany

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • National Cancer Center Hospital East, Kashiwa/JP

  • University Hospital Seidman Cancer Center, Cleveland, OH

  • Sidney Kimmel Comprehensive Cancer Center, 1650, Baltimore, MD

  • City of Hope, Duarte, CA

  • University of Chicago Medicine and Biolo, Chicago, IL, USA

  • Amgen Inc, Thousand Oaks, CA

Locations

  • United States

  • Australia

  • Spain

  • United Kingdom

  • Netherlands

  • France

  • Germany

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Small cell lung cancer

Biomarkers

  • Delta Like Canonical Notch Ligand 3

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved